Achilles Therapeutics announced the appointment of Dr. Markus Dangl as Chief Scientific Officer. Dr. Dangl joins Achilles from Medigene AG where he spent three years as Senior Vice President for Research and Non-clinical Development. During his tenure he led the non-clinical development of MDG1011. Prior to that Markus spent 15 years at Roche in Germany, Singapore and the US, holding various managerial positions with increasing responsibility and was involved in the design and execution of multiple oncology projects.